{"groups":[{"description":"All participants enrolled.\n\nBortezomib: Bortezomib will be administered as a 3-5 second bolus IV injection at the dose of 0.7 mg/m\\^2 on days 1, 8, 15, and 22 of each 42 day cycle.\n\nPatients will undergo nine 42-day cycles. At the end of this (day 378), patients will be assessed for bone remodeling changes. Evaluation for toxicities will be evaluated at the beginning of each cycle.","id":"FG000","title":"Arm -1 Bortezomib"}],"periods":[{"milestones":[{"achievements":[{"groupId":"FG000","numSubjects":"17"}],"type":"STARTED"},{"achievements":[{"groupId":"FG000","numSubjects":"17"}],"type":"COMPLETED"},{"achievements":[{"groupId":"FG000","numSubjects":"0"}],"type":"NOT COMPLETED"}],"title":"Overall Study"}]}